Special Issue

Adeno-Associated Virus (AAV) for Gene Therapy

Message from the Guest Editor

Adeno-associated virus (AAV) based vector have arguably emerged as the leading gene therapy modality. Below is a (non-inclusive) list of areas that are of special interest for the current special quest issue of *Viruses*.

- Approaches to reduce the vector dose without negatively influencing transduction efficiencies (e.g., the development of viruses with a more favorable transduction profile, more efficient routes of administration, understanding the basic biology of AAVs – particular in vivo models etc.);
- Developing methods to determine the human tropism of AAV serotypes/variants;
- Identifying the best model(s) to study AAV tropism, based on knowledge gained by the ability to determine the *human* tropism;
- Reduction of an innate immune response upon vector administration;
- Reduction of an adaptive immune response due to treatment with AAV vectors;
- Approaches to mitigate the deleterious effect of preexisting immunity against the AAV serotype/variant used;
- The development of methods that allow vector readministration:
- AAV vector manufacturing platforms;
- AAV vector quality control.

Guest Editor

Dr. Thomas Weber Spark Therapeutics Inc., Philadelphia, PA, USA

Deadline for manuscript submissions

closed (30 September 2024)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/177437

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

